Otros idiomas Nippon Shinyaku Co., Ltd.

Acciones

4516

JP3717600005

Mercado cerrado - Japan Exchange Otros sitios de cotización 08:00:00 13/05/2024			Varia. Cinco días.	Varia. 1 de enero.
3.893 ^JPY	-11,98 %		-11,30 %	-22,08 %

10/04	NIPPON SHINYAKU CO., LTD. : El Jefferies & Co. continua con un recomendación de compra	ZM
09/02	Vicore Pharma firma un acuerdo de licencia para un candidato a fármaco contra la fibrosis pulmonar idiopática	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Nippon Shinyaku : Outline of Consolidated Financial Results for the Year Ended March 31, 2024	10/05
Interim report January-March 2024	03/05
Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW	16/04
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases	05/04
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System	04/04
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan	26/03
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan	26/03
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan	25/03
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100	18/03
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03
Year-end report 2023	28/02
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	09/02
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan	09/02
Nippon Shinyaku : The European Commission Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy	21/12
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (2Q FY2023)(Script+Q&A(Summary))P	07/12
Capricor Therapeutics Announces $23 Million Registered Direct Offering	02/10/23
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare	31/08/23
Nippon Shinyaku Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2023	10/08/23
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (1Q FY2023	10/08/23
Nippon Shinyaku : Outline of Consolidated Financial Results for the First Quarter Ende	10/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Nippon Shinyaku Co., Ltd.

Acciones

4516

JP3717600005

Otros idiomas

Filtros